Repligen to acquire BioLife Solutions for about $1.5 billion in cash and stock

 

• Repligen expects the BioLife Solutions acquisition to be accretive to results following closing.
• Repligen reports preliminary Q2 2026 revenue growth of about 12%, including approximately 13% organic revenue growth.

https://finviz.com/stock?t=RGEN&ty=c&ta=1&p=d